{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:46Z","timestamp":1792801726804,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008426","name":"Friedrich-Baur-Stiftung","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008426","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","award":["201307040012"],"award-info":[{"award-number":["201307040012"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"crossref","award":["2018.087.1"],"award-info":[{"award-number":["2018.087.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"crossref","award":["2018.087.1"],"award-info":[{"award-number":["2018.087.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["Quantitative Biosciences Munich"],"award-info":[{"award-number":["Quantitative Biosciences Munich"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SFB 1243 project A10"],"award-info":[{"award-number":["SFB 1243 project A10"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Research Council","award":["638218"],"award-info":[{"award-number":["638218"]}],"id":[{"id":"https:\/\/ror.org\/0472cxd90","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Human Frontier Science Program","award":["RGP0008\/2015"],"award-info":[{"award-number":["RGP0008\/2015"]}]},{"name":"Bavarian Elite Graduate School \u201ci-target\u201d"},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapy of acute myeloid leukemia has experienced considerable advances, however novel target antigens continue to be sought after. To this end, unbiased approaches for surface protein detection are limited and integration with other data types, such as gene expression and somatic mutational burden, are poorly utilized. The Cell Surface Capture technology provides an unbiased, discovery-driven approach to map the surface proteins on cells of interest. Yet, direct utilization of primary patient samples has been limited by the considerable number of viable cells needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we optimized the Cell Surface Capture protocol to enable direct interrogation of primary patient samples and applied our optimized protocol to a set of samples from patients with acute myeloid leukemia (AML) to generate the AML surfaceome. We then further curated this AML surfaceome to exclude antigens expressed on healthy tissues and integrated mutational burden data from hematologic cancers to further enrich for targets which are likely to be essential to leukemia biology. Finally, we validated our findings in a separate cohort of AML patient samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our protocol modifications allowed us to double the yield in identified proteins and increased the specificity from 54 to 80.4% compared to previous approaches. Using primary AML patient samples, we were able to identify a total of 621 surface proteins comprising the AML surfaceome. We integrated this data with gene expression and mutational burden data to curate a set of robust putative target antigens. Seventy-six proteins were selected as potential candidates for further investigation of which we validated the most promising novel candidate markers, and identified CD148, ITGA4 and Integrin beta-7 as promising targets in AML. Integrin beta-7 showed the most promising combination of expression in patient AML samples, and low or absent expression on healthy hematopoietic tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Taken together, we demonstrate the feasibility of a highly optimized surfaceome detection method to interrogate the entire AML surfaceome directly from primary patient samples and integrate this data with gene expression and mutational burden data to achieve a robust, multiomic target identification platform. This approach has the potential to accelerate the unbiased target identification for immunotherapy of AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40364-022-00390-4","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T20:02:51Z","timestamp":1654804971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Integrated multiomic approach for identification of novel immunotherapeutic targets in AML"],"prefix":"10.1186","volume":"10","author":[{"given":"Thomas","family":"K\u00f6hnke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Haubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"B\u00fccklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerulf","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Krupka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Solis-Mezarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"390_CR1","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","volume":"38","author":"O Dufva","year":"2020","unstructured":"Dufva O, P\u00f6l\u00f6nen P, Br\u00fcck O, Ker\u00e4nen MAI, Klievink J, Mehtonen J, et al. Immunogenomic Landscape of Hematological Malignancies. Cancer Cell. 2020;38:380-399.e13.","journal-title":"Cancer Cell"},{"key":"390_CR2","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","volume":"4","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu J, Lai C, Reeder S, Church SE, Hood T, Lourdusamy A, et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Adv. 2020;4:5011\u201324.","journal-title":"Blood Adv"},{"key":"390_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","volume":"32","author":"F Perna","year":"2017","unstructured":"Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell. 2017;32:506-519.e5.","journal-title":"Cancer Cell"},{"key":"390_CR4","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2010-02-271270","volume":"116","author":"A Hofmann","year":"2010","unstructured":"Hofmann A, Gerrits B, Schmidt A, Bock T, Bausch-Fluck D, Aebersold R, et al. Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells. Blood. 2010;116:e26-34.","journal-title":"Blood"},{"key":"390_CR5","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1182\/blood-2012-11-468702","volume":"121","author":"P Mirkowska","year":"2013","unstructured":"Mirkowska P, Hofmann A, Sedek L, Slamova L, Mejstrikova E, Szczepanski T, et al. Leukemia surfaceome analysis reveals new disease-associated features. Blood. 2013;121:e149\u201359.","journal-title":"Blood"},{"key":"390_CR6","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/s41467-022-29304-6","volume":"13","author":"N Kawashima","year":"2022","unstructured":"Kawashima N, Ishikawa Y, Kim JH, Ushijima Y, Akashi A, Yamaguchi Y, et al. Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells. Nat Commun. 2022;13:1624.","journal-title":"Nat Commun"},{"key":"390_CR7","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1038\/bcj.2015.19","volume":"5","author":"E Saland","year":"2015","unstructured":"Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, et al. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer J. 2015;5:e297.","journal-title":"Blood Cancer J"},{"key":"390_CR8","doi-asserted-by":"publisher","first-page":"e105602","DOI":"10.1371\/journal.pone.0105602","volume":"9","author":"CA Gedye","year":"2014","unstructured":"Gedye CA, Hussain A, Paterson J, Smrke A, Saini H, Sirskyj D, et al. Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity. PLoS One. 2014;9:e105602.","journal-title":"PLoS One"},{"key":"390_CR9","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1158\/2159-8290.CD-15-0298","volume":"5","author":"GK Behbehani","year":"2015","unstructured":"Behbehani GK, Samusik N, Bjornson ZB, Fantl WJ, Medeiros BC, Nolan GP. Mass cytometric functional profiling of acute myeloid leukemia defines cell-cycle and immunophenotypic properties that correlate with known responses to therapy. Cancer Discov. 2015;5:988\u20131003.","journal-title":"Cancer Discov"},{"key":"390_CR10","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"390_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"C Krupka","year":"2016","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, K\u00f6hnke T, et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30:484\u201391.","journal-title":"Leukemia"},{"key":"390_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","volume":"123","author":"C Krupka","year":"2014","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, B\u00f6geholz J, K\u00f6hnke T, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123:356\u201365.","journal-title":"Blood"},{"key":"390_CR13","doi-asserted-by":"publisher","first-page":"e0120925","DOI":"10.1371\/journal.pone.0120925","volume":"10","author":"B Vick","year":"2015","unstructured":"Vick B, Rothenberg M, Sandh\u00f6fer N, Carlet M, Finkenzeller C, Krupka C, et al. An advanced preclinical mouse model for acute myeloid leukemia using patients\u2019 cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS One. 2015;10:e0120925.","journal-title":"PLoS One"},{"key":"390_CR14","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nbt.1532","volume":"27","author":"B Wollscheid","year":"2009","unstructured":"Wollscheid B, Bausch-Fluck D, Henderson C, O\u2019Brien R, Bibel M, Schiess R, et al. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol. 2009;27:378\u201386.","journal-title":"Nat Biotechnol"},{"key":"390_CR15","doi-asserted-by":"publisher","first-page":"e0121314","DOI":"10.1371\/journal.pone.0121314","volume":"10","author":"D Bausch-Fluck","year":"2015","unstructured":"Bausch-Fluck D, Wanjin H, Hofmann A, Bock T, Frei AP, Cerciello F, et al. A mass spectrometric-derived cell surface protein atlas. PLoS One. 2015;10:e0121314.","journal-title":"PLoS One"},{"key":"390_CR16","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/bioinformatics\/bty109","volume":"34","author":"JG P\u00e9rez-Silva","year":"2018","unstructured":"P\u00e9rez-Silva JG, Araujo-Voces M, Quesada V. nVenn: generalized, quasi-proportional Venn and Euler diagrams. Bioinformatics. 2018;34:2322\u20134.","journal-title":"Bioinformatics"},{"key":"390_CR17","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, Alotaibi AS, B\u00fccklein V, Subklewe M. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia. 2021;35:1843\u201363.","journal-title":"Leukemia"},{"key":"390_CR18","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1182\/blood.V91.8.2800.2800_2800_2809","volume":"91","author":"MA de la Fuente-Garc\u0131\u0301a","year":"1998","unstructured":"de la Fuente-Garc\u0131\u0301a MA, Nicol\u00e1s JM, Freed JH, Palou E, Thomas AP, Vilella R, et al. CD148 is a membrane protein tyrosine phosphatase present in all hematopoietic lineages and is involved in signal transduction on lymphocytes. Blood. 1998;91:2800\u20139.","journal-title":"Blood"},{"key":"390_CR19","doi-asserted-by":"publisher","first-page":"e112753","DOI":"10.1371\/journal.pone.0112753","volume":"9","author":"K Takahashi","year":"2014","unstructured":"Takahashi K, Matafonov A, Sumarriva K, Ito H, Lauhan C, Zemel D, et al. CD148 tyrosine phosphatase promotes cadherin cell adhesion. PLoS One. 2014;9:e112753.","journal-title":"PLoS One"},{"key":"390_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1242\/jcs.00879","volume":"117","author":"S Kellie","year":"2004","unstructured":"Kellie S, Craggs G, Bird IN, Jones GE. The tyrosine phosphatase DEP-1 induces cytoskeletal rearrangements, aberrant cell-substratum interactions and a reduction in cell proliferation. J Cell Sci. 2004;117:609\u201318.","journal-title":"J Cell Sci"},{"key":"390_CR21","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/j.1538-7836.2010.03865.x","volume":"8","author":"S Ellison","year":"2010","unstructured":"Ellison S, Mori J, Barr AJ, Senis YA. CD148 enhances platelet responsiveness to collagen by maintaining a pool of active Src family kinases. J Thromb Haemost. 2010;8:1575\u201383.","journal-title":"J Thromb Haemost"},{"key":"390_CR22","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1161\/ATVBAHA.112.300447","volume":"32","author":"J Mori","year":"2012","unstructured":"Mori J, Wang Y-J, Ellison S, Heising S, Neel BG, Tremblay ML, et al. Dominant role of the protein-tyrosine phosphatase CD148 in regulating platelet activation relative to protein-tyrosine phosphatase-1B. Arterioscler Thromb Vasc Biol. 2012;32:2956\u201365.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"390_CR23","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1182\/blood.V112.11.1766.1766","volume":"112","author":"L Miguet","year":"2008","unstructured":"Miguet L, Fornecker LM, Felden C, Gervais C, Herbrecht R, Sanglier S, et al. Proteomic analysis of chronic malignant B-Cell derived microparticles reveals CD148 as a potential antigenic marker for mantle cell lymphoma diagnosis. Blood. 2008;112:1766\u20131766.","journal-title":"Blood"},{"key":"390_CR24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/ijlh.13467","volume":"43","author":"A Gautam","year":"2021","unstructured":"Gautam A, Sreedharanunni S, Sachdeva MUS, Rana S, Kashyap D, Bose P, et al. The relative expression levels of CD148 and CD180 on clonal B cells and CD148\/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow \u2013 Results from a single centre pilot study. Int J Lab Hematol. 2021;43:1123\u201331.","journal-title":"Int J Lab Hematol"},{"key":"390_CR25","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.7150\/jca.40955","volume":"11","author":"Y Sun","year":"2020","unstructured":"Sun Y, Li S, Yu W, Chen C, Liu T, Li L, et al. CD148 serves as a prognostic marker of gastric cancer and hinders tumor progression by dephosphorylating EGFR. J Cancer. 2020;11:2667\u201378.","journal-title":"J Cancer"},{"key":"390_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S, Perna F, K\u00f6hnke T, Schmidt C, Berman S, Augsberger C, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64\u201374.","journal-title":"Leukemia"},{"key":"390_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/bjh.14647","volume":"178","author":"P Strati","year":"2017","unstructured":"Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, et al. CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2017;178:99\u2013105.","journal-title":"Br J Haematol"},{"key":"390_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/cyto.b.21384","volume":"94","author":"CE Gooden","year":"2018","unstructured":"Gooden CE, Jones P, Bates R, Shallenberger WM, Surti U, Swerdlow SH, et al. CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia\/small lymphocytic lymphoma. Cytometry B Clin Cytom. 2018;94:129\u201335.","journal-title":"Cytometry B Clin Cytom"},{"key":"390_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","volume":"32","author":"P Bulian","year":"2014","unstructured":"Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, N\u00fcckel H, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol. 2014;32:897\u2013904.","journal-title":"J Clin Oncol"},{"key":"390_CR30","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.3390\/ijms21186691","volume":"21","author":"DB Gissi","year":"2020","unstructured":"Gissi DB, Fabbri VP, Gabusi A, Lenzi J, Morandi L, Melotti S, et al. Pre-operative evaluation of DNA methylation profile in oral squamous cell carcinoma can predict tumor aggressive potential. Int J Mol Sci. 2020;21:6691.","journal-title":"Int J Mol Sci"},{"key":"390_CR31","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.21037\/tcr-20-3315","volume":"9","author":"J Cheng","year":"2020","unstructured":"Cheng J, Han J, Lin C. A comprehensive assessment of the prognostic role of cell adhesion molecules in acute myeloid leukemia. Transl Cancer Res. 2020;9:7605\u201318.","journal-title":"Transl Cancer Res"},{"key":"390_CR32","doi-asserted-by":"crossref","unstructured":"Full reference: Choudhury SR, Ashby C, Tytarenko R, Wang Y, Patel PH, Mikulasova A, et al. Abstract 5324: Intragenic DNA-hypomethylation promotes overexpression of ITGB7 in MF subgroup of multiple myeloma. Cancer Res. 2018;78(13_Supplement):5324.","DOI":"10.1158\/1538-7445.AM2018-5324"},{"key":"390_CR33","doi-asserted-by":"publisher","first-page":"10415","DOI":"10.2147\/OTT.S228631","volume":"12","author":"Z Chai","year":"2019","unstructured":"Chai Z, Yang Y, Gu Z, Cai X, Ye W, Kong L, et al. Recombinant Viral Capsid Protein L2 (rVL2) of HPV 16 Suppresses Cell Proliferation and Glucose Metabolism via ITGB7\/C\/EBP\u03b2 Signaling Pathway in Cervical Cancer Cell Lines. Onco Targets Ther. 2019;12:10415\u201325.","journal-title":"Onco Targets Ther"},{"key":"390_CR34","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1080\/07853890.2021.1937694","volume":"53","author":"T Xu","year":"2021","unstructured":"Xu T, Liu J, Xia Y, Wang Z, Li X, Gao Q. Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis. Ann Med. 2021;53:916\u201328.","journal-title":"Ann Med"},{"key":"390_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jid.2017.05.026","volume":"138","author":"JHB Hardenberg","year":"2018","unstructured":"Hardenberg JHB, Braun A, Sch\u00f6n MP. A Yin and Yang in Epithelial Immunology: The Roles of the \u03b1E(CD103)\u03b27 Integrin in T Cells. J Invest Dermatol. 2018;138:23\u201331.","journal-title":"J Invest Dermatol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-022-00390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-022-00390-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-022-00390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T20:06:02Z","timestamp":1654805162000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-022-00390-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1186\/s40364-022-00390-4","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]},"assertion":[{"value":"3 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient specimens used in this study were obtained after informed consent in accordance with the Declaration of Helsinki and approval by the Institutional Review Board of the Ludwig-Maximilians-Universit\u00e4t (Munich, Germany).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.S. has received research support from Amgen, Gilead, Miltenyi Biotec, Morphosys, Roche, and Seattle Genetics, sits on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics, serves on the speakers' bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer, and has served as a consultant\/advisor to Amgen, BMS, Celgene, Gilead, Pfizer, Novartis, and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}